Katherine Anne Sumpter

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.

R. Kurek, T. Ruhstaller, M. Valladares-Ayerbes, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.